Research is key to improving the lives of individuals with Angelman syndrome and to finding a cure. As the largest non-governmental funder of Angelman syndrome-specific research, the Angelman Syndrome Foundation (ASF) has invested more than $8 million in Angelman syndrome research to date, supporting more than 78 projects worldwide in the quest to find treatments and a cure. Treatments resulting from the ASF’s $8 million investment in research help individuals with Angelman syndrome live better lives today and lead to better lives tomorrow, but requires ongoing financial support.
UPDATE: Upcoming Angelman Syndrome clinical trial
Ovid Therapeutics and Lundbeck A/S pharmaceuticals have entered into a worldwide licensing agreement for Gaboxadol, a drug that Ovid plans to use in separate upcoming clinical trials to treat Angelman syndrome and Fragile X syndrome.
See a recap of the 2015 Scientific Symposium.
AS researchers have devoted their careers to finding treatments and a cure for Angelman syndrome. When they could have worked in hundreds of other fields of scientific research and discovery, they chose AS—and because of that choice, our loved ones with AS are living better lives today with the hope of even better lives tomorrow.
Use the form below to send a note of gratitude, and the ASF will share your message with AS researchers at the upcoming Scientific Symposium.